

BRASKEM S.A.
C.N.P.J. nº 42.150.391/0001-70
N.I.R.E. 29300006939
Companhia Aberta
FATO RELEVANTE

A Braskem S.A. ("Braskem" ou "Companhia") (Ticker B3: BRKM3, BRKM5, e BRKM6; NYSE: BAK; LATIBEX: XBRK), em continuidade ao Fato Relevante divulgado em 24 de agosto de 2026 em relação ao protocolo de um pedido de recuperação extrajudicial pela Companhia e certas controladas ("Recuperação Extrajudicial"), vem comunicar aos seus acionistas e ao mercado em geral que forneceu a determinados titulares e gestores de investimentos de uma ou mais das Notas Seniores e Debêntures emitidas ou garantidas pela Braskem ("Investidores") as seguintes informações não públicas relacionadas à Braskem e às suas controladas ("Informações Compartilhadas"), no contexto das negociações relacionadas a atualização do plano de Recuperação Extrajudicial ("Plano de RE"):

1. Materiais de discussão da Braskem contendo seu plano de negócios atualizado, entregues pela Braskem em 31 de agosto de 2026, nos termos do Plano de RE;
2. Materiais de discussão da Braskem contendo projeções atualizadas de fluxo de caixa e outras informações financeiras e operacionais, entregues pela Braskem em 30 de setembro de 2026, nos termos do Plano de RE;
3. Principais termos e condições comerciais propostos para o Plano de RE atualizado, entregues pela Braskem em 23 de outubro de 2026 (a "Proposta da Braskem"); e
4. Principais termos e condições comerciais propostos para o Plano de RE atualizado, entregues pelos Investidores em 24 de outubro de 2026 (a "Proposta dos Investidores").

Nos termos dos acordos de confidencialidade celebrados em setembro de 2026 entre a Braskem e os Investidores (coletivamente, os "Acordos de Confidencialidade"), a Braskem concordou em divulgar publicamente as Informações Compartilhadas após o término do prazo estabelecido nos Acordos de Confidencialidade. As Informações Compartilhadas estão anexas ao presente Fato Relevante e são fornecidas para cumprir as obrigações da Braskem nos termos dos Acordos de Confidencialidade e em conformidade com as normas legais aplicáveis.

Após diversas reuniões presenciais realizadas nesse período entre a Braskem, seus principais acionistas e os Investidores, nenhuma das propostas foi aceita, e as partes ainda não chegaram a um acordo quanto aos termos de uma reestruturação.

A Braskem espera dar continuidade às discussões e negociações a respeito dos termos do Plano de RE atualizado com os Investidores, e permanece comprometida com o diálogo com os Investidores e seus

demais credores financeiros, com o objetivo de cumprir o marco previsto na Cláusula 1.1(iv) do Protocolo de Negociação até o prazo acordado entre a Braskem e a maioria exigida de credores signatários nos termos do Plano de RE (marco esse que foi prorrogado para 30 de outubro de 2026).

As Informações Compartilhadas contêm projeções a respeito de preços, volume de vendas, consumo e fornecimento de matéria prima, custos, produção e taxa de utilização, bem como de indicadores financeiros da Braskem, até 2035. As projeções apresentadas são dados hipotéticos e previsões que refletem as expectativas atuais da administração da Braskem e não devem ser interpretadas como garantias ou promessas de desempenho, estando sujeitas a riscos e incertezas associadas às condições econômicas, regulatórias e concorrenciais dos mercados em que a Braskem atua, podendo, assim, diferir materialmente em relação aos números e resultados a serem efetivamente registrados pela Braskem.

A Companhia esclarece que as projeções contidas nas Informações Compartilhadas da Braskem não devem ser consideradas como guidance e foram preparadas no contexto da Recuperação Extrajudicial.

A Companhia manterá o mercado informado sobre quaisquer desdobramentos materiais relacionados ao tema, em cumprimento às legislações aplicáveis.

Informações adicionais podem ser obtidas junto ao Departamento de Relações com Investidores através do telefone (11) 3576-9531 ou do e-mail braskem-ri@braskem.com.br.

São Paulo, 24 Outubro de 2026

Carlos Augusto Machado Pereira de Almeida Brandão

Diretor Financeiro e de Relações com Investidores

Braskem S.A.

DECLARAÇÕES PROSPECTIVAS

Este Fato Relevante pode conter declarações prospectivas. Essas declarações não se tratam de fatos históricos, sendo baseadas na atual visão e estimativas da administração da Companhia quanto a futuras circunstâncias econômicas e outras, condições do setor, desempenho e resultados financeiros incluindo qualquer impacto em potencial ou projetado do evento geológico em Alagoas e procedimentos legais relacionados nos negócios, condição financeira e resultados operacionais da Companhia. As palavras "prevê", "acredita", "estima", "espera", "planeja", "objetiva" e outras expressões similares, quando referentes à Companhia, têm o objetivo de identificar declarações prospectivas. Afirmações referentes a possíveis resultados de processos legais e administrativos, implementação de estratégias de operações e financiamentos e planos de investimento, orientação de operações futuras, o objetivo de ampliar os seus esforços para atingir os macro objetivos sustentáveis divulgados pela Companhia, bem como fatores ou tendências que afetem a condição financeira, liquidez ou resultados operacionais da Companhia são exemplos de declarações prospectivas. Tais afirmações refletem as visões atuais da administração da Companhia e estão sujeitas a diversos riscos e incertezas, muitos dos quais estão fora do controle da Companhia. Não há garantia de que os eventos, tendências ou resultados esperados vão de fato ocorrer. As declarações são embasadas em várias premissas e fatores, incluindo, mas não se limitando a, condições gerais econômicas e de mercado, condições da indústria, fatores operacionais, disponibilidade, desenvolvimento e acessibilidade financeira de novas tecnologias. Qualquer mudança em tais premissas ou fatores, incluindo o impacto projetado do evento geológico em Alagoas e procedimentos legais relacionados e o impacto sem precedentes nos negócios, funcionários, prestadores de serviço, acionistas, investidores e demais públicos de relacionamento da Companhia pode fazer com que os resultados efetivos sejam significativamente diferentes das expectativas atuais. Consulte os relatórios arquivados na Comissão de Valores Mobiliários - CVM, em particular os fatores discutidos nas seções para uma discussão completa sobre os riscos e outros fatores que podem impactar quaisquer declarações prospectivas contidas neste documento. Este Fato Relevante não é uma oferta de valores mobiliários para venda no Brasil, quaisquer valores mobiliários não podem ser oferecidos ou vendidos no Brasil sem registro ou isenção de registro, qualquer oferta pública de valores mobiliários a ser feita no Brasil será elaborado por meio de prospecto que poderá ser obtido na Braskem e que conterá informações detalhadas sobre a Braskem e a administração, bem como as demonstrações financeiras.

PRIVILEGED & CONFIDENTIAL – FOR DISCUSSION PURPOSES ONLY
CONFIDENTIAL SETTLEMENT COMMUNICATION SUBJECT TO FRE 408
AND ITS EQUIVALENTS

PROJETO CATALYST

Cleansing Materials

Disclaimer

These materials and the information contained herein (these “Cleansing Materials”) were prepared solely to facilitate discussions with certain members of an ad hoc group of creditors (the “Investors”) of Braskem S.A. (together with its subsidiaries and affiliates, the “Company”) that were subject to confidentiality agreements and were not prepared with a view toward public disclosure. The Cleansing Materials should not be relied upon to make an investment decision with respect to the Company. The Cleansing Materials speak only as of the date when such information was delivered to the Investors or their representatives and should not be regarded as an indication that the Company or any third party considers the Cleansing Materials to be material non-public information or a reliable prediction of future events, and the Cleansing Materials should not be relied upon as such. Neither the Company nor any third party makes any representation regarding the accuracy or completeness of the Cleansing Materials, whether when first delivered to the Investors or their representatives, as of the date hereof or any other past or future date. Any forward-looking statements are based on current assumptions and expectations and involve risks and uncertainties.

The Cleansing Materials include certain values for illustrative purposes only, and such values are not the result of, and do not represent, actual valuations, estimates, forecasts or projections of the Company or any third party and should not be relied upon as such. Actual values or results may differ materially from those expressed or implied in these Cleansing Materials. Neither the Company, its advisors nor any third party makes any representation to any person regarding the accuracy or completeness of any Cleansing Materials or undertakes any obligation to update the Cleansing Materials to reflect circumstances existing after the date when the Cleansing Materials were prepared or conveyed or to reflect the occurrence of future events, even if any or all of the assumptions underlying the Cleansing Materials become or are shown to be incorrect.

These materials and information contained in the Cleansing Materials are made in connection with potential settlement, compromise, or business resolution discussions. Pursuant to Federal Rule of Evidence 408 and applicable state and foreign law equivalents, this document and any information contained herein shall not be construed as an admission of liability, fault, or wrongdoing, and shall not be admissible as evidence to prove or disprove the validity or amount of any disputed claim or for impeachment purposes in any litigation or proceeding.

These Cleansing Materials do not constitute (and shall not be construed as) an offer to sell, a solicitation of an offer to buy, a commitment to lend, underwrite or provide financing, or a recommendation with respect to any security, loan or transaction.

Contexto

Desde o protocolo do Plano de RE^(a) e a celebração dos Acordos de Confidencialidade, a Braskem e os Investidores, por meio de seus respectivos assessores, prepararam e trocaram diversas propostas e informações, sendo as mais recentes as seguintes (os “Cleansing Materials”):

1. Materiais de discussão da Braskem contendo seu plano de negócios atualizado, entregues pela Braskem em 31 de agosto de 2026, nos termos do Plano de RE^(b);
2. Materiais de discussão da Braskem contendo projeções atualizadas de fluxo de caixa e outras informações financeiras e operacionais, entregues pela Braskem em 30 de setembro de 2026, nos termos do Plano de RE;
3. Principais termos e condições comerciais propostos para o Plano de RE atualizado, entregues pela Braskem em 23 de outubro de 2026 (a “Proposta da Braskem”); e
4. Principais termos e condições comerciais propostos para o Plano de RE atualizado, entregues pelos Investidores em 24 de outubro de 2026 (a “Proposta dos Investidores”).

Os Cleansing Materials seguem anexos.

Após diversas reuniões presenciais realizadas nesse período entre a Braskem, seus principais acionistas e os Investidores, nenhuma das propostas foi aceita, e as partes ainda não chegaram a um acordo quanto aos termos de uma reestruturação.

A Braskem espera dar continuidade às discussões e negociações a respeito dos termos do Plano de RE atualizado com os Investidores, e permanece comprometida com o diálogo com os Investidores e seus demais credores financeiros, com o objetivo de cumprir o marco previsto na Cláusula 1.1(iv) do Protocolo de Negociação até o prazo acordado entre a Braskem e a maioria exigida de credores signatários nos termos do Plano de RE (marco esse que foi prorrogado para 30 de outubro de 2026).

(a) Os termos iniciados em letra maiúscula utilizados e não definidos neste documento terão o significado a eles atribuído no Fato Relevante datado de 24 de outubro de 2026.

(b) As informações contidas na Proposta da Braskem são precisas na data de sua entrega, não foram atualizadas desde então e não devem ser utilizadas para qualquer outra finalidade.

I Plano de Negócios Atualizado

Disclaimer

This document is delivered pursuant to, and in compliance with, Section 1.1.(ii) of the Negotiation Framework attached as Schedule 1.1.61 to the Extrajudicial Reorganization Plan dated as of August 24, 2026 (the “EJ Plan”) jointly filed by Braskem S.A., Braskem Netherlands B.V., Braskem Netherlands Inc. B.V., Braskem Trading & Shipping B.V., Braskem Netherlands Finance B.V. and Braskem America Finance Company (collectively, the “Debtors”) and which was adhered to by certain financial creditors of the Debtors representing, on a consolidated basis, 39.6% of the financial debt of the Debtors subject to the EJ Plan (the “Signatory Creditors”). Capitalized terms used and not otherwise defined herein will have the meaning given in the EJ Plan.

This document and the information contained to the recipient pursuant to that certain confidentiality agreements by and between the recipient and Braskem S.A. listed in Annex A hereto (the “NDAs”) and constitutes Confidential Information for purpose thereof. By accessing this document and in accordance with Section 4.3 of the Negotiation Framework, the recipient agrees to: (i) treat all the information contained herein as Confidential Information and maintain the confidentiality of all such information; (ii) not reproduce or disclose, in whole or in part, any information contained herein to any person other than as permitted under the relevant NDA; and (iii) comply with any other obligation under the NDA with respect to, or in connection with, such information.

All analysis contained herein has been prepared based upon the Company’s internal records. All information in this document is subject to verification, correction or completion without notice. Lazard has not assumed any responsibility for independent verification of any of the information contained herein and it has relied on such information being complete and accurate in all material respects. No representation or warranty, either express or implied, is made by any person as to the accuracy, reliability or completeness of the information presented herein. Neither the Company, Lazard, nor any of their respective subsidiaries, affiliates, directors, officers, agents, employees or advisors accepts any liability whatsoever for any loss or damage of any kind arising out of the use of all or any part of this document.

This document does not purport to contain all of the information that a recipient may desire in investigating or deciding to enter into any transaction with, the Company or any subsidiary or affiliate thereof, or otherwise take any course of action, and should not be relied upon to form the basis of, be relied on in connection with, or act as an inducement or recommendation to enter into, any transaction or take any other action whatsoever. This document does not constitute and is not to be construed as an offer to sell or a solicitation to buy, exchange or grant consent to any securities and does not constitute any form of commitment or recommendation on the part of the Company or Lazard or any of their respective subsidiaries, affiliates, associated companies or advisors.

This document should not be regarded by the recipient as a substitute for the exercise of its own judgment to enter into any transaction with the Company or any subsidiary or affiliate thereof or otherwise take any course of action. The risk, merit and suitability of any such transaction should be independently evaluated and any person considering such transaction is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other considerations relating to such transaction prior to entering into any such transaction or otherwise taking any course of action.

By receipt of this document, the recipient acknowledges that it is not relying on the Company or Lazard for tax, accounting, legal or other advice, and that the recipient should receive separate and qualified tax, accounting, legal and other professional advice in connection with any transaction or course of conduct.

Nothing contained herein shall be deemed to be a recommendation from the Company or Lazard to any party to enter into any transaction or to take any course of action. This document provides summary information only and is being delivered solely for informational and discussion purposes. The use of this document for any other purpose is not authorized. This document is not intended to provide a basis for evaluating any transaction, to take any course of action or to be construed as a basis for any other matter.

This document speaks only as of the date hereof, all of which is subject to change, and neither the Company, Lazard nor any other person is under any obligation to update, keep current, bring-down, review or reaffirm the information herein. Under no circumstances should the delivery of this document imply that any information or analyses included in this document would be the same if made as of any other date.

This document includes forward-looking statements. All statements other than statements of historical fact or relating to present facts or current conditions included in this document are forward-looking statements. Forward-looking statements give the Company’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts.

Such forward-looking statements are based on certain assumptions and current expectations and projections about future events and trends that may affect the Company’s business and are not guarantees of future performance. Several of those assumptions and expectations are based on, or rely upon, past results or have not necessarily been recently updated or reassessed. Although the Company believes those assumptions are reasonable in light of the available information, they are inherently subject to various risks and uncertainties. Recipients of this document are cautioned that any such forward-looking statements are and will be, as the case may be, subject to many risks, uncertainties and other unknown factors, including those relating to the operations and business of the Company. These and various other factors may adversely affect the estimates and assumptions on which these forward-looking statements are based, many of which are beyond the Company’s control.

The inclusion of forward-looking statements should not be regarded as a representation that any such transaction or event shall be consummated or that the Company will achieve its respective plans, estimates and expectations with respect to such transactions or events. Actual results and capital and other financial conditions may differ materially from those included in these statements due to a variety of factors. In light of the risks and uncertainties described above, the future events and circumstances discussed in this document might not occur and are not guarantees of future performance.


Forward-looking statements speak only as of the date on which they are made. Nothing contained in this document is, or shall be relied upon as, a promise or representation as to the past, present or future. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. RECIPIENTS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS.

This document may include certain financial measures that are not presented in accordance with International Financial Reporting Standards (“IFRS”). These non-IFRS measures are an addition to, and not a substitute for or superior to, measures of financial performance prepared in accordance with an IFRS alternative to net income or any other measures derived in accordance with IFRS. The Company believes that these non-IFRS measures of financial results provide useful supplemental information to creditors about the Company. These non-IFRS financial measures may differ from the calculations of other companies and, as a result, may not be comparable to similarly titled measures presented by other companies.


Evolução dos Principais Spreads – *Referência Internacional*

Spreads calculados com base nas referências internacionais de preços de produtos e matérias-primas

PE – Nafta (US\$/ton)^(a)




PP US – PGP (US\$/ton)^(c)




Fonte: Braskem.
Nota: Considera spreads médios anuais.
(a) Spread PE: (HDPE US*40% + LDPE US*30% + LLDPE US*30%) – Naphtha ARA.
(b) Spread PP: PP Asia – Naphtha ARA.

PP – Nafta (US\$/ton)^(b)



PP EU – PGP (US\$/ton)^(d)



(c) Spread PP US: PP North America – PGP North America.
(d) Spread PP EU: PP West Europe – PGP West Europe.


Evolução dos Principais Spreads – *Preços Efetivos*

Spreads calculados com base nos preços efetivos de venda dos produtos e nos preços efetivos de compra das matérias-primas

Preço de Venda Doméstica de PE – Nafta (US\$/ton)

Evolução Trimestral em 2026


1T26	2T26	3T26	4T26
807	1,725	818	796



PP US – PGP (US\$/ton)

Evolução Trimestral em 2026


1T26	2T26	3T26	4T26
381	718	474	395



Preço de Venda Doméstica de PP – Nafta (US\$/ton)

Evolução Trimestral em 2026


1T26	2T26	3T26	4T26
816	1,342	861	795



PP EU – PGP (US\$/ton)

Evolução Trimestral em 2026


1T26	2T26	3T26	4T26
95	676	223	209



Fonte: Braskem.
Nota: Considera spreads efetivos anuais médios.


Premissas de Volume Vendido e de Matérias-Primas

Volume Total Vendido (kton) e Taxa de Utilização (%) por Geografia



Fonte: Braskem.

Consumo das Principais Matérias-Primas (kton) e Fonte de Produção de Etileno (%)



Projeções Anuais de P&L – *Status Quo*
(Em milhões de dólares, exceto quando indicado)

	2021A	2022A	2023A	2024A	2025A	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
Brasil	12,879	13,418	9,898	10,189	9,259	10,809	10,249	10,434	10,564	11,751	11,891	12,441	12,673	13,129	13,560
US & Europa	6,033	4,550	3,504	3,630	2,927	3,443	3,238	3,239	3,564	3,799	3,933	4,080	4,174	4,281	4,409
Outros	(88)	79	235	15	133	(100)	-	-	-	-	-	-	-	-	-
Receita Líquida	18,824	18,046	13,637	13,834	12,319	14,152	13,487	13,673	14,129	15,550	15,825	16,521	16,848	17,410	17,969
(–) COGS	(13,433)	(16,014)	(13,038)	(12,826)	(11,706)	(12,351)	(12,177)	(12,126)	(12,418)	(13,477)	(13,477)	(14,036)	(14,236)	(14,558)	(14,890)
(=) Lucro Bruto	5,391	2,033	599	1,009	613	1,801	1,310	1,547	1,711	2,073	2,348	2,486	2,612	2,853	3,079
Margem Bruta (%)	28.6%	11.3%	4.4%	7.3%	5.0%	12.7%	9.7%	11.3%	12.1%	13.3%	14.8%	15.0%	15.5%	16.4%	17.1%
(–) SG&A	(668)	(760)	(823)	(743)	(731)	(811)	(813)	(803)	(814)	(829)	(853)	(865)	(880)	(895)	(910)
Despesas Administrativas	(128)	(155)	(141)	(137)	(182)	(175)	(193)	(217)	(220)	(222)	(227)	(231)	(235)	(239)	(243)
Despesas Comerciais	(157)	(165)	(189)	(202)	(232)	(303)	(330)	(290)	(292)	(298)	(312)	(313)	(318)	(323)	(329)
Unidade Corporativa	(342)	(403)	(376)	(365)	(296)	(304)	(290)	(296)	(302)	(309)	(315)	(321)	(327)	(332)	(338)
Outros	(42)	(36)	(117)	(39)	(22)	(29)	-	-	-	-	-	-	-	-	-
(–) ORD	(185)	(354)	(142)	(339)	294	(53)	31	51	45	43	39	36	33	29	26
(–) D&A	(170)	(183)	(122)	(112)	(85)	(133)	(128)	(130)	(121)	(124)	(117)	(113)	(110)	(108)	(106)
(=) EBIT	4,368	736	(487)	(185)	91	804	401	665	821	1,162	1,417	1,544	1,654	1,879	2,089
Margem EBIT (%)	23.2%	4.1%	(3.6%)	(1.3%)	0.7%	5.7%	3.0%	4.9%	5.8%	7.5%	9.0%	9.3%	9.8%	10.8%	11.6%
(+) D&A	651	759	819	710	625	615	702	712	812	891	726	704	688	676	668
(+/-) Outros Ajustes	4	300	280	321	(208)	41	-	-	-	-	-	-	-	-	-
(=) EBITDA	5,024	1,796	612	845	508	1,460	1,103	1,377	1,633	2,053	2,143	2,248	2,342	2,555	2,757
Margem EBITDA (%)	26.7%	10.0%	4.5%	6.1%	4.1%	10.3%	8.2%	10.1%	11.6%	13.2%	13.5%	13.6%	13.9%	14.7%	15.3%

Fonte: Braskem.

Projeções Anuais de Fluxo de Caixa – *Status Quo*

(Em milhões de dólares, exceto quando indicado)

	YTG 2026 ^(a)	2027	2028	2029	2030	2031	2032	2033	2034	2035
EBITDA	190	1,103	1,377	1,633	2,053	2,143	2,248	2,342	2,555	2,757
(±) Capital de Giro Operacional	295	51	(27)	(61)	(181)	(42)	(82)	(47)	(74)	(73)
(–) Capex de Manutenção	(313)	(551)	(574)	(508)	(556)	(580)	(594)	(608)	(621)	(634)
(–) Alagoas e Penalidades	(116)	(123)	(175)	(177)	(141)	(158)	(131)	(121)	(132)	(146)
(±) Outros	(427)	(237)	(244)	(266)	(390)	(787)	(495)	(535)	(590)	(648)
(=) Fluxo de Caixa Op. Recorrente	(371)	243	357	620	786	575	946	1,031	1,139	1,256
(±) Capital de Giro Financeiro	(584)	(1,032)	(82)	(87)	(68)	(72)	(71)	(71)	(71)	(70)
(–) Capex Estratégico	(23)	(249)	(357)	(414)	(46)	-	-	-	-	-
(=) CFADS	(978)	(1,038)	(82)	119	672	503	875	960	1,068	1,185
(–) Juros Bonds e Debêntures / CRAs	(108)	(513)	(478)	(438)	(366)	(295)	(257)	(218)	(182)	(114)
(–) Juros RCF, Bancos e ECAs	(69)	(36)	(10)	(5)	(2)	(1)	-	-	-	-
(–) Amortizações	(1,184)	(302)	(1,417)	(404)	(1,590)	(894)	(21)	(1,000)	(850)	-
(=) Geração / Consumo de Caixa	(2,338)	(1,889)	(1,986)	(728)	(1,286)	(687)	597	(258)	36	1,071
Saldo de Caixa BoP	1,146	(1,203)	(3,057)	(5,077)	(5,724)	(6,972)	(7,667)	(7,073)	(7,341)	(7,311)
(±) Geração / Consumo de Caixa	(2,338)	(1,889)	(1,986)	(728)	(1,286)	(687)	597	(258)	36	1,071
(±) Variação Cambial	(11)	36	(34)	81	38	(8)	(3)	(9)	(6)	6
Saldo de Caixa EoP	(1,203)	(3,057)	(5,077)	(5,724)	(6,972)	(7,667)	(7,073)	(7,341)	(7,311)	(6,234)
(–) Caixa Restrito	(107)	(111)	(101)	(104)	(107)	(94)	(97)	(99)	(102)	(104)
Saldo de Caixa Livre EoP	(1,310)	(3,168)	(5,178)	(5,828)	(7,079)	(7,762)	(7,170)	(7,440)	(7,412)	(6,337)

Considerações

- A Ver página seguinte para detalhamento adicional
- B Assume o cronograma de vencimentos das LCs conforme contratado, sem renovação, e a renovação das operações de desconto de recebíveis/clientes. De forma ilustrativa, assume que o pagamento das LCs com vencimento em jun/jul-2026 ocorre em ago-2026. Ver página seguinte para detalhamento adicional
- C Assume o serviço da dívida conforme atualmente contratado

Fonte: Braskem.
(a) Valores de Agosto-2026 em diante.

Projeções Anuais de Capital de Giro – *Status Quo*
(Em milhões de dólares, exceto quando indicado)

	YTG 2026 ^(a)	2027	2028	2029	2030	2031	2032	2033	2034	2035
Capital de Giro Operacional										
Contas a Receber	1,310	1,262	1,278	1,323	1,456	1,482	1,544	1,578	1,631	1,683
Dias de Receita	37	38	34	34	34	34	34	34	34	34
Variação em Contas a Receber	53	47	(15)	(45)	(133)	(26)	(62)	(34)	(53)	(52)
Estoque	2,304	2,165	2,152	2,211	2,396	2,392	2,485	2,526	2,584	2,643
Dias de COGS	70	70	65	65	65	65	65	65	65	65
Variação em Estoque	151	140	13	(59)	(185)	4	(93)	(41)	(57)	(59)
Impostos a Recuperar	779	751	761	787	867	882	919	939	971	1,002
Dias de Receita	22	23	20	20	20	20	20	20	20	20
Variação em Impostos a Recuperar	101	28	(9)	(27)	(79)	(15)	(37)	(20)	(31)	(31)
Contas a Pagar	913	858	853	876	949	948	985	1,001	1,024	1,047
Dias de COGS	27	28	26	26	26	26	26	26	26	26
Variação em Contas a Pagar	(20)	(55)	(5)	23	73	(1)	37	16	23	24
Outras Contas a Pagar / Receber	1,793	1,684	1,674	1,720	1,864	1,861	1,933	1,966	2,010	2,057
Dias de COGS	51	54	51	51	51	51	51	51	51	51
Var. em Outras Contas a Pagar/Receber	9	(109)	(10)	46	144	(3)	72	32	45	46
Variação de Capital de Giro	295	51	(27)	(61)	(181)	(42)	(82)	(47)	(74)	(73)
Capital de Giro Financeiro										
LCs (Fornecedores)										
BoP	1,277	502	-	-	-	-	-	-	-	-
(+) Emissão	-	-	-	-	-	-	-	-	-	-
(-) Amortização	(774)	(502)	-	-	-	-	-	-	-	-
(+/-) Variação Cambial	-	-	-	-	-	-	-	-	-	-
EoP	502	-	-	-	-	-	-	-	-	-
Custo Financeiro	(18)	(19)	-	-	-	-	-	-	-	-
Clientes (Factoring)										
BoP	954	876	863	858	836	835	836	836	837	837
(+) Emissão	3,056	7,290	6,718	6,760	6,621	6,618	6,618	6,618	6,618	6,618
(-) Amortização	(3,114)	(7,301)	(6,726)	(6,773)	(6,617)	(6,618)	(6,618)	(6,618)	(6,618)	(6,618)
(+) Juros Acruidos	1	2	-	-	-	-	-	-	-	-
(+/-) Variação Cambial	(22)	(4)	4	(9)	(4)	0	0	0	0	0
EoP	876	863	858	836	835	836	836	837	837	837
Custo Financeiro	(39)	(89)	(74)	(74)	(72)	(72)	(71)	(71)	(71)	(70)

Fonte: Braskem.
(a) Valores de Agosto-2026 em diante.

II

Fluxo de Caixa Mensal Atualizado

PRIVILEGED & CONFIDENTIAL

Disclaimer

This document is delivered pursuant to, and in compliance with, Section 2.1.(iii) of the Negotiation Framework attached as Schedule 1.1.61 to the Extrajudicial Reorganization Plan dated as of August 24, 2026 (the “EJ Plan”) jointly filed by Braskem S.A., Braskem Netherlands B.V., Braskem Netherlands Inc. B.V., Braskem Trading & Shipping B.V., Braskem Netherlands Finance B.V. and Braskem America Finance Company (collectively, the “Debtors”) and which was adhered to by certain financial creditors of the Debtors representing, on a consolidated basis, 39.6% of the financial debt of the Debtors subject to the EJ Plan (the “Signatory Creditors”). Capitalized terms used and not otherwise defined herein will have the meaning given in the EJ Plan.

This document and the information contained to the recipient pursuant to that certain confidentiality agreements by and between the recipient and Braskem S.A. listed in Annex A hereto (the “NDAs”) and constitutes Confidential Information for purpose thereof. By accessing this document and in accordance with Section 4.3 of the Negotiation Framework, the recipient agrees to: (i) treat all the information contained herein as Confidential Information and maintain the confidentiality of all such information; (ii) not reproduce or disclose, in whole or in part, any information contained herein to any person other than as permitted under the relevant NDA; and (iii) comply with any other obligation under the NDA with respect to, or in connection with, such information.

All analysis contained herein has been prepared based upon the Company’s internal records. All information in this document is subject to verification, correction or completion without notice. Lazard has not assumed any responsibility for independent verification of any of the information contained herein and it has relied on such information being complete and accurate in all material respects. No representation or warranty, either express or implied, is made by any person as to the accuracy, reliability or completeness of the information presented herein. Neither the Company, Lazard, nor any of their respective subsidiaries, affiliates, directors, officers, agents, employees or advisors accepts any liability whatsoever for any loss or damage of any kind arising out of the use of all or any part of this document.

This document does not purport to contain all of the information that a recipient may desire in investigating or deciding to enter into any transaction with, the Company or any subsidiary or affiliate thereof, or otherwise take any course of action, and should not be relied upon to form the basis of, be relied on in connection with, or act as an inducement or recommendation to enter into, any transaction or take any other action whatsoever. This document does not constitute and is not to be construed as an offer to sell or a solicitation to buy, exchange or grant consent to any securities and does not constitute any form of commitment or recommendation on the part of the Company or Lazard or any of their respective subsidiaries, affiliates, associated companies or advisors.

This document should not be regarded by the recipient as a substitute for the exercise of its own judgment to enter into any transaction with the Company or any subsidiary or affiliate thereof or otherwise take any course of action. The risk, merit and suitability of any such transaction should be independently evaluated and any person considering such transaction is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other considerations relating to such transaction prior to entering into any such transaction or otherwise taking any course of action.

By receipt of this document, the recipient acknowledges that it is not relying on the Company or Lazard for tax, accounting, legal or other advice, and that the recipient should receive separate and qualified tax, accounting, legal and other professional advice in connection with any transaction or course of conduct.

Nothing contained herein shall be deemed to be a recommendation from the Company or Lazard to any party to enter into any transaction or to take any course of action. This document provides summary information only and is being delivered solely for informational and discussion purposes. The use of this document for any other purpose is not authorized. This document is not intended to provide a basis for evaluating any transaction, to take any course of action or to be construed as a basis for any other matter.

This document speaks only as of the date hereof, all of which is subject to change, and neither the Company, Lazard nor any other person is under any obligation to update, keep current, bring-down, review or reaffirm the information herein. Under no circumstances should the delivery of this document imply that any information or analyses included in this document would be the same if made as of any other date.

This document includes forward-looking statements. All statements other than statements of historical fact or relating to present facts or current conditions included in this document are forward-looking statements. Forward-looking statements give the Company’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts.

Such forward-looking statements are based on certain assumptions and current expectations and projections about future events and trends that may affect the Company’s business and are not guarantees of future performance. Several of those assumptions and expectations are based on, or rely upon, past results or have not necessarily been recently updated or reassessed. Although the Company believes those assumptions are reasonable in light of the available information, they are inherently subject to various risks and uncertainties. Recipients of this document are cautioned that any such forward-looking statements are and will be, as the case may be, subject to many risks, uncertainties and other unknown factors, including those relating to the operations and business of the Company. These and various other factors may adversely affect the estimates and assumptions on which these forward-looking statements are based, many of which are beyond the Company’s control.

The inclusion of forward-looking statements should not be regarded as a representation that any such transaction or event shall be consummated or that the Company will achieve its respective plans, estimates and expectations with respect to such transactions or events. Actual results and capital and other financial conditions may differ materially from those included in these statements due to a variety of factors. In light of the risks and uncertainties described above, the future events and circumstances discussed in this document might not occur and are not guarantees of future performance.

Forward-looking statements speak only as of the date on which they are made. Nothing contained in this document is, or shall be relied upon as, a promise or representation as to the past, present or future. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. RECIPIENTS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS.

This document may include certain financial measures that are not presented in accordance with International Financial Reporting Standards (“IFRS”). These non-IFRS measures are an addition to, and not a substitute for or superior to, measures of financial performance prepared in accordance with an IFRS alternative to net income or any other measures derived in accordance with IFRS. The Company believes that these non-IFRS measures of financial results provide useful supplemental information to creditors about the Company. These non-IFRS financial measures may differ from the calculations of other companies and, as a result, may not be comparable to similarly titled measures presented by other companies.

Fluxo de Caixa Mensal Atualizado – Standstill

(Em milhões de dólares, exceto quando indicado)

	Realizado	Projetado		
	Aug-26	Sep-26	Oct-26	Nov-26
EBITDA	93	68	62	(6)
(±) Capital de Giro – Operacional	37	56	137	110
(–) Capex de Manutenção	(45)	(71)	(70)	(72)
(–) Alagoas e Penalidades	(12)	(26)	(20)	(17)
(±) Outros	(238)	(48)	(51)	3
(=) Fluxo de Caixa Operacional Recorrente	(165)	(22)	58	17
(±) Capital de Giro – Financeiro	A 58	242	(54)	(83)
(–) Capex Estratégico	(2)	(7)	(5)	(5)
(=) CFADS	(108)	212	(1)	(70)
(–) Dívida Financeira – Juros e Amortizações	B -	-	-	-
(=) Geração / Consumo de Caixa	(108)	212	(1)	(70)
Saldo de Caixa BoP	1,143	1,012	1,243	1,216
(±) Geração / Consumo de Caixa	(108)	212	(1)	(70)
(±) Variação Cambial	(22)	18	(26)	(1)
Saldo de Caixa EoP	1,012	1,243	1,216	1,145
(–) Caixa Restrito	(143)	(167)	(165)	(164)
Saldo de Caixa Livre EoP	869	1,076	1,051	981

Considerations

O Fluxo de Caixa considera valores realizados de Agosto e projetados de Setembro a Novembro

- A Assume que não há pagamentos das cartas de crédito e considera a cessão continua de recebíveis (True Sale). A linha de crédito comercial com a Petrobras está considerada nessa linha
- B Assume que não há pagamentos de serviço da dívida

III

Proposta da Braskem e Proposta dos Investidores

Disclaimer

This document (the “Proposal”) is delivered in connection with the Extrajudicial Reorganization Plan dated as of August 24, 2026 (the “EJ Plan”) jointly filed by Braskem S.A., Braskem Netherlands B.V., Braskem Netherlands Inc. B.V., Braskem Trading & Shipping B.V., Braskem Netherlands Finance B.V. and Braskem America Finance Company (collectively, the “Debtors”) and which, as of the date hereof, has been adhered to by certain financial creditors of the Debtors representing, on a consolidated basis, 40.3% of the financial debt of the Debtors subject to the EJ Plan (the “Signatory Creditors”). Capitalized terms used and not otherwise defined herein will have the meaning given in the EJ Plan.

This Proposal contains a non-binding summary of the indicative principal commercial terms and conditions of the Updated Plan. This Proposal does not constitute an offer or a commitment by any Debtor or any Main Shareholder to enter into or otherwise support, as applicable, an Updated Plan in the terms set forth herein and may be subject to changes. The final terms and conditions of the Updated Plan, if and when agreed between the relevant parties, are contingent upon the approval of each Debtor and each Main Shareholder, in accordance with governance requirements and procedures, as well as being contingent upon obtaining and complying with any additional approvals, authorizations and requirements under applicable law and subject to further review of corporate, tax and accounting matters. None of the terms and conditions set forth herein shall be binding upon or enforceable against the Debtors except until such time any such terms and conditions are set forth in the Updated Plan that is duly confirmed by the applicable court and the definitive binding agreements implementing such terms and conditions.

Pursuant to Section 2.7.1 of the Plan, neither this Proposal, nor any other proposal made, resolution adopted in respect of proposals made by the Debtors, or agreement reached by the Debtors and the Signatory Creditors party to the Negotiation Framework in relation to matters that directly affect the Main Shareholders (including, without limitation, commitments, the form and structure of capital contributions, dilution levels and parameters, and the terms and conditions for the conversion of debt into equity) shall be binding upon or enforceable against the Main Shareholders unless expressly consented to in writing by the Main Shareholders in accordance with their applicable corporate governance rules.

This Proposal is being delivered to the recipient pursuant to that certain confidentiality agreements by and between the recipient and Braskem S.A. listed in Annex A hereto (the “NDAs”) and constitutes Confidential Information for purpose thereof. By accessing this Proposal and in accordance with Section 4.3 of the Negotiation Framework, the recipient agrees to: (i) treat all the information contained herein as Confidential Information and maintain the confidentiality of all such information; (ii) not reproduce or disclose, in whole or in part, any information contained herein to any person other than as permitted under the relevant NDA; and (iii) comply with any other obligation under the NDA with respect to, or in connection with, such information.

This Proposal has been prepared by Lazard Assessoria Financeira Ltda (“Lazard”), Makalu Partners (“Makalu”), Cleary Gottlieb Steen & Hamilton LLP (“CGSH”) and Emunhoz Advogados (“EMunhoz” and, together with Lazard, Makalu and CGSH, the “Debtors Advisors”) on behalf of the Debtors for delivery to Houlihan Lokey Capital, Inc., Davis Polk & Wardwell LLP, Pinheiro Guimarães Advogados and the Signatory Creditors. The Debtors Advisors prepared this Proposal based on information that is publicly available and/or provided by the Debtors. The Debtors Advisors have relied upon the accuracy and completeness of such information and have not independently verified it.

Neither the Debtors Advisors nor the Debtors make any representation or warranty, express or implied, as to the accuracy or completeness of this Proposal. Each recipient must conduct its own independent investigation and analysis and may not rely on this Proposal or any statements by the Debtors Advisors or the Debtors as the basis for any investment, credit, legal, tax, accounting or other decision.

This Proposal contains forward-looking statements, including projections, forecasts, estimates, and other statements regarding future events, financial performance, business strategies, and anticipated results. These forward-looking statements are based on current expectations, assumptions, and estimates of the Debtors that are subject to significant business, economic, regulatory, and competitive uncertainties, many of which are beyond the Debtors’ control. Actual results may differ materially from those expressed or implied in such forward-looking statements. No representation or warranty is made that any forward-looking statement will be achieved or will prove to be correct. Recipients are cautioned not to place undue reliance on any forward-looking statements contained herein.

This Proposal is being provided in connection with potential settlement, compromise, or business resolution discussions. Pursuant to Federal Rule of Evidence 408 and applicable equivalent laws and regulations of any state or other country or jurisdiction (including Brazil and Netherlands), this Proposal and any information contained herein shall not be construed as an admission of liability, fault, or wrongdoing, and shall not be admissible as evidence to prove or disprove the validity or amount of any disputed claim or for impeachment purposes in any litigation or proceeding. This Proposal is provided for negotiation and discussion purposes only.

Term Sheet | Proposta da Braskem (10/23) e Proposta dos Investidores (10/24) ^(1/6)

The final terms and conditions of the Updated Plan, if and when agreed between the relevant parties, are contingent upon the approval of each Debtor and each Main Shareholder, in accordance with governance requirements and procedures

		Proposta da Braskem (10/23)	Proposta dos Investidores (10/24)
Relief Period	Tenor	- Transaction to be implemented on a day-one basis: Upfront Debt-to-Equity Conversion and shareholder equity contribution at closing of the Equity Rights Offering (subject to the deferred disbursement) - Contingent Equity Contribution and Contingent Debt-to-Equity Conversion in June 2029, in the amount necessary (if any) to achieve the Minimum Metrics, subject to Sequencing and caps described below	Agreed, but excluding deferred equity disbursement and Contingent Equity Contribution. All shareholder equity contribution to be disbursed at closing
	Commercial Credit Line	- Commercial Credit Line to be maintained on its current terms for 3 years (i.e., through June 2029) - Amount: US\$470 million^(a) - Outstanding balance to be fully repaid at maturity	Treatment of Commercial Credit Line TBD
Long-Term Restructuring	Structure	- Long-Term Restructuring to be achieved through a combination of (i) an equity commitment backstopped by the Main Shareholders or third parties and (ii) debt conversion into equity - To be implemented at closing and on a contingent basis in June 2029, as set forth below	- Agreed, but excluding deferred equity disbursement and Contingent Equity Contribution. All shareholder equity contribution to be disbursed at closing - Contingent Debt-to-Equity Conversion to be limited to Convertible Takeback Debt
	Timing & Minimum Metrics	- Contingent Equity Contribution and Contingent Debt-to-Equity Conversion in June 2029, in the amount necessary (if any) to achieve the Minimum Metrics, subject to Sequencing and caps described below - Minimum Metrics: Net Leverage of 4.0x, excluding L/Cs from the calculation - Definition and measurement period of Net Leverage: TBD	Agreed, but excluding Contingent Equity Contribution. All shareholder equity contribution to be disbursed at closing

(a) Contracted value of the Commercial Credit Line is R\$2,350 million (AHG Counterproposal: US\$470 million to be interpreted as the entire value of the Commercial Credit Line).

Term Sheet | Proposta da Braskem (10/23) e Proposta dos Investidores (10/24) ^(2/6)

The final terms and conditions of the Updated Plan, if and when agreed between the relevant parties, are contingent upon the approval of each Debtor and each Main Shareholder, in accordance with governance requirements and procedures

		Proposta da Braskem (10/23)	Proposta dos Investidores (10/24)
Treatment of Claims	Overview & Default Option	- Four options (Default Option, Option A, Option B and Option C) available to all Subject Claims (~US\$10.9 billion) Default Option: New 2060 1% PIK takeback debt - Early payment terms: TBD - Creditors must agree not to pursue enforcement / recoveries against non-debtor obligors as a condition to electing non-default options, subject to election mechanics and documentation to be agreed – mechanics TBD	Agreed
	Option A (L/Cs)	- Creditors that participate in a new L/C line with US\$[200] million of incremental capacity receive reinstated L/Cs, subject to negotiation with the L/C providers: Reinstated L/Cs - Maturity: [7]-year maturity - Interest: [SOFR rate + margin] - Collateral: [TBD] New [\$200 million] L/C availability - Maturity: [7]-year maturity - Interest: [SOFR rate + margin] - Collateral: [TBD] - Available only to existing L/C providers - Structure TBD	- Creditors that participate in a new L/C line with \$[200] million of incremental capacity receive reinstated L/Cs and no Convertible Debt Reinstated L/Cs - Maturity: 7-year maturity - Interest: SOFR rate - Collateral: Shared first lien with secured takeback debt on assets and equity of European operations New [\$200 million] L/C availability - Maturity: 7-year maturity - Interest: SOFR rate + [margin] - Collateral: Shared first lien with secured takeback debt on collateral package - Available only to existing L/C providers - Structure TBD such that L/Cs are treated in manner consistent with past practice

Term Sheet | Proposta da Braskem (10/23) e Proposta dos Investidores (10/24) ^(3/6)

The final terms and conditions of the Updated Plan, if and when agreed between the relevant parties, are contingent upon the approval of each Debtor and each Main Shareholder, in accordance with governance requirements and procedures

		Proposta da Braskem (10/23)	Proposta dos Investidores (10/24)
Treatment of Claims			
	Option B	- Open to all creditors; those that elect Option B receive their pro rata share of a combination of Secured Takeback Debt and equity (Debt-to-Equity Conversion): Secured Takeback Debt - Amount: 71% of electing claims (up to ~US\$6.8 billion, assuming all L/C providers elect Option A and subject to Option C election); to be adjusted pro rata for actual elections - Includes a portion of up to US\$[0.5–1.0] billion convertible into equity in June 2029, as per the Contingent Debt-to-Equity Conversion (security, structure, rates, collateral – TBD) - Maturity: amortizations beginning 2033; schedule TBD - Interest Rate: increase of 125bps over the current weighted-average interest rate 100% PIK toggle for 3 years (i.e., through June 2029), subject to a 100bps PIK premium - Collateral: assets and equity of U.S. operations, other assets TBD, subject to required consents - Cash Sweep: Annual excess cash sweep of all cash above US\$2.0 billion, calculation to exclude proceeds from Equity Rights Offering Upfront Debt-to-Equity Conversion - Amount: 29% of electing claims (up to ~US\$2.8 billion, assuming all L/C providers elect Option A and subject to Option C election); to be adjusted pro rata for actual elections - Conversion: mandatory and in full at closing, simultaneously with the Equity Rights Offering - Conversion Price: based on current Market Price (mechanics TBD) Contingent Debt-to-Equity Conversion: see next page	- Open to all creditors; those that elect Option B receive their pro rata share of a combination of Secured Takeback Debt, Convertible Takeback Debt, and equity <u>Note:</u> Treatment across existing debt instruments, including term and rate, remains an open point, subject to further discussion among the parties Secured Takeback Debt - Amount: Remaining Option B claims after Debt-to-Equity Conversion and Convertible Takeback Debt (approximately ~\$7.3 billion^(a) / ~76¢ assuming all L/C providers elect Option A) - Maturity: TBD extension - Interest: Interest rates of existing instruments to be increased in a manner that results in a weighted average increase from ~6.8% to ~8.5% p.a.^(b) 50% PIK toggle through December 2027, subject to a 175bps PIK premium - Collateral: Comprehensive collateral package including first lien on assets and equity of U.S., Europe, and Brazil operations and equity of BAKIDE - Cash Sweep: Annual excess cash sweep of all cash above \$1.0 billion - Calculation to exclude proceeds from the Equity Rights Offering for TBD period Debt-to-Equity Conversion - Amount: \$1.85 billion (~19.3¢) - To be reduced by any amount of nominal debt reduction provided by Option C election - Reduced amounts to be allocated to the Secured Takeback Debt - Conversion Price: R\$2.00 / share Convertible Takeback Debt: see next page

(a) As of August 24, 2026.

(b) Current weighted average interest rate of the Company's debt excluding L/Cs.

Term Sheet | Proposta da Braskem (10/23) e Proposta dos Investidores (10/24) ^(4/6)

The final terms and conditions of the Updated Plan, if and when agreed between the relevant parties, are contingent upon the approval of each Debtor and each Main Shareholder, in accordance with governance requirements and procedures

		Proposta da Braskem (10/23)	Proposta dos Investidores (10/24)
Treatment of Claims	Option B (cont'd)	– Contingent Debt-to-Equity Conversion • Amount: up to US\$[0.5–1.0] billion (final amount TBD subject to negotiations) • Conversion: in June 2029, proportionally with the Contingent Equity Contribution, in the amount necessary (if any) to achieve the Minimum Metrics, subject to Sequencing • Conversion Price: based on Market Price at the time of conversion (mechanics TBD)	– Convertible Takeback Debt • Amount: \$450 million (~4.7¢) ○ To be reduced by any amount of nominal debt reduction in excess of \$1.85 billion provided by Option C election ○ Reduced amounts to be allocated to the Secured Takeback Debt • Interest Rate: Accretion on Conversion Price equivalent to 4% p.a. • Conversion Price: R\$2.00 / share, to reduce by 4% p.a. • Conversion: Mandatory conversion in June 2029 of the amount necessary to achieve 4.0x OtC Net Leverage, capped at \$450 million total conversion ○ Optional Conversion: Optional conversion at creditors' election ○ Remaining Convertible Debt (i.e., if not fully converted): Exchanged into Secured Takeback Debt at 110% (accreted amount through the end of relief period at 4% p.a.)
	Option C	• Open to all creditors; those that elect Option C receive Secured Takeback Debt: – Amount: [TBD]% of electing claims – Maturity: same as Option B Secured Takeback Debt – Interest Rate: same as Option B Secured Takeback Debt (including 3-year PIK toggle) – Collateral: same as Option B Secured Takeback Debt	• Construction of an option that provides additional secured takeback debt in lieu of Debt-to-Equity Conversion / Convertible Takeback Debt agreed; TBD economics and takeback percentage

Term Sheet | Proposta da Braskem (10/23) e Proposta dos Investidores (10/24) ^(5/6)

The final terms and conditions of the Updated Plan, if and when agreed between the relevant parties, are contingent upon the approval of each Debtor and each Main Shareholder, in accordance with governance requirements and procedures

		Proposta da Braskem (10/23)	Proposta dos Investidores (10/24)
Equity Rights Offering	Amount & Backstop	- At closing, the Company will carry out a capital increase (“Equity Rights Offering”) open to all current shareholders and third parties, on the following terms: Amount: Follow-on of US\$2.25 billion, of which US\$1.2 billion will be backstopped by the Main Shareholders or third parties, with commitment provided today - Commitment subscribed in full at Equity Rights Offering closing, with 50% disbursed at closing and 50% disbursed 12 months after closing Contingent Equity Contribution: additional commitment of up to US\$0.5 billion by the Main Shareholders or third parties, provided today, to be contributed in June 2029 in the amount necessary (if any) to achieve the Minimum Metrics, subject to Sequencing Backstop Parties: Main Shareholders may designate third-party backstop parties without creditor approval, so long as such third-party complies with certain credit and sanctions eligibility requirements TBD	- At closing, the Company will carry out a capital increase (“Equity Rights Offering”) open to all current shareholders and third parties, on the following terms: Amount: Follow-on of \$2.25 billion, of which \$1.85 billion will be backstopped by the Main Shareholders or third parties, with commitment provided today Backstop Parties: Any third party (other than the Main Shareholders) that may provide backstop commitment shall be subject to creditor approval prior to plan approval
	Sequencing	- Equity contributions and debt-to-equity conversions to be implemented as follows: (i) At closing: Equity Rights Offering (including the US\$1.2 billion backstop, subject to the deferred disbursement) and Upfront Debt-to-Equity Conversion of US\$2.8 billion (each at its own pricing terms) (ii) In June 2029: Contingent Equity Contribution (up to US\$0.5 billion) and Contingent Debt-to-Equity Conversion (up to US\$[0.5–1.0] billion), applied pari passu and proportionally, i.e., pro rata to their respective maximum amounts (each at its own pricing terms), in the amount necessary (if any) to achieve the Minimum Metrics	- Equity contributions and debt-to-equity conversions to be implemented as follows: (i) At Closing: Equity Rights Offering (including the \$1.85 billion backstop) and Upfront Debt-to-Equity Conversion of \$1.85 billion (each at its own pricing terms) (ii) In June 2029: Contingent Debt-to-Equity Conversion (up to \$450 million), in the amount necessary (if any) to achieve the Minimum Metrics
	Pricing	Pricing: 20% discount to the current Market Price, applicable to all participants subscribing with new money, including current shareholders exercising pre-emptive or priority rights pursuant to articles 170, 81, and 171 of Law No. 6,404/76 - Contingent Equity Contribution pricing: 20% discount to the Market Price at the time of disbursement (mechanics TBD)	Pricing: R\$1.60 / share (20% discount to Debt Conversion Price)
	Timing & Structure	Timing: At closing, simultaneously with the Upfront Debt-to-Equity Conversion; contingent components in June 2029 (see Sequencing) Implementation and Structure: To be designed in a manner satisfactory to the shareholders, creditors and the Company - Structure to contemplate maintenance of existing governance framework	Agreed in principle; governance to be discussed

Term Sheet | Proposta da Braskem (10/23) e Proposta dos Investidores (10/24) ^(6/6)

The final terms and conditions of the Updated Plan, if and when agreed between the relevant parties, are contingent upon the approval of each Debtor and each Main Shareholder, in accordance with governance requirements and procedures

		Proposta da Braskem (10/23)	Proposta dos Investidores (10/24)
Others	Braskem Idesa & Transforma Rio	- The Updated Plan will permit: - The Company to implement the Braskem Idesa transaction - Strategic investments related to the Transforma Rio project, conditional upon acceptance by creditors holding at least 50% of Secured Takeback Debt (mechanics TBD)	- BAKIDE implementation conditioned on closing of the transaction - Implementation of any strategic capex, including Transforma Rio, conditional upon acceptance by at least [50]% of Signatory Creditors
	Cash Sweep & Asset Sales	Cash Sweep: As set forth in Secured Takeback Debt terms Asset Sales: [TBD]	Cash Sweep: As set forth in Secured Takeback Debt terms Asset Sales: Any proceeds must be used to repay Secured Takeback Debt at par